Operates a contract development and manufacturing (CDMO) business providing pharmaceutical and medical-device development, testing, and GMP manufacturing services. In parallel, it develops and intends to license its BTLS liposomal platform for drug delivery across the blood-brain barrier, including CNS and oncology programs.
